Literature DB >> 23436113

Paraneoplastic neurological syndromes: general treatment overview.

Aurélien Viaccoz1, Jérôme Honnorat.   

Abstract

OPINION STATEMENT: Major recent discoveries have bringing out a revised definition of paraneoplastic neurological syndromes (PNS), bringing out the concept of antibody-mediated neurological disorders, triggered or not by cancer. Classification of these diseases is not based anymore on the clinical pattern or an underlying tumor, but on the location of the targeted antigens. Indeed, evolution, response to treatment, and pathophysiology are radically different according to the associated antibodies. In some patients with newly described antibodies targeting cell-surface antigens, humoral immunity seems to play a direct role and a dramatic improvement is observed with immunomodulator treatments. In these patients, an associated tumor is less frequent. Conversely, patients with antibodies directed against intracellular targets are, in most cases, characterized by a high degree of irreversible neuronal death mediated by cytotoxic T-cells and do not improve after immunomodulator treatments. In these patients, an associated tumor is highly frequent and must be cured as soon as possible. A third group of patients can be identified with anti-GAD65 and anti-Amphiphysin antibodies. In patients with these antibodies, the efficiency of immunomodulator treatments is less clear as well as the type of immune response that could be a mix between humoral and cellular. In this last group, the antigen is intracellular, but patients may improve with immunomodulator treatments and associated tumors are rare. Thus, identification of associated antibodies should be prompt and the treatment guided according the identified antibody. Mainstream of treatment include the quest of a tumor and its cure. Immunotherapy must be promptly initiated, targeting humoral, or cellular immune response, or both, according to the associated antibodies. Furthermore, in some situations such as Lambert-Eaton Myasthenic Syndromes and Stiff-Person Syndromes, symptomatic drugs can be useful to control the symptoms.

Entities:  

Year:  2013        PMID: 23436113     DOI: 10.1007/s11940-013-0220-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  106 in total

1.  Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor.

Authors:  P Sillevis Smitt; A Kinoshita; B De Leeuw; W Moll; M Coesmans; D Jaarsma; S Henzen-Logmans; C Vecht; C De Zeeuw; N Sekiyama; S Nakanishi; R Shigemoto
Journal:  N Engl J Med       Date:  2000-01-06       Impact factor: 91.245

2.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

Authors:  F Graus; F Keime-Guibert; R Reñe; B Benyahia; T Ribalta; C Ascaso; G Escaramis; J Y Delattre
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

3.  [Anti-GAD antibodies in paraneoplastic cerebellar ataxia associated with limbic encephalitis and autonomic dysfunction].

Authors:  C Carra-Dalliere; E Thouvenot; A Bonafé; F Ducray; J Touchon; M Charif
Journal:  Rev Neurol (Paris)       Date:  2012-03-07       Impact factor: 2.607

Review 4.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

Review 5.  3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.

Authors:  Paul W Wirtz; Maarten J Titulaer; Joop Ma van Gerven; Jan J Verschuuren
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

6.  Successful treatment of paraneoplastic cerebellar degeneration with Rituximab.

Authors:  Marcello Esposito; P Penza; G Orefice; A Pagano; E Parente; A Abbadessa; V Bonavita
Journal:  J Neurooncol       Date:  2007-10-09       Impact factor: 4.130

7.  Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers.

Authors:  Bruno Giometto; Wolfgang Grisold; Roberta Vitaliani; Francesc Graus; Jérôme Honnorat; Guido Bertolini
Journal:  Arch Neurol       Date:  2010-03

8.  GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders.

Authors:  A Boronat; L Sabater; A Saiz; J Dalmau; F Graus
Journal:  Neurology       Date:  2011-03-01       Impact factor: 9.910

9.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Authors:  I Elovaara; S Apostolski; P van Doorn; N E Gilhus; A Hietaharju; J Honkaniemi; I N van Schaik; N Scolding; P Soelberg Sørensen; B Udd
Journal:  Eur J Neurol       Date:  2008-09       Impact factor: 6.089

10.  Clinical analysis of anti-Ma2-associated encephalitis.

Authors:  Josep Dalmau; Francesc Graus; Alberto Villarejo; Jerome B Posner; Deborah Blumenthal; Brian Thiessen; Albert Saiz; Patricio Meneses; Myrna R Rosenfeld
Journal:  Brain       Date:  2004-06-23       Impact factor: 13.501

View more
  5 in total

1.  The Utility of FDG-PET/CT in Clinically Suspected Paraneoplastic Neurological Syndrome: A Literature Review and Retrospective Case Series.

Authors:  Mark P Maskery; Jonathan Hill; John R Cain; Hedley C A Emsley
Journal:  Front Neurol       Date:  2017-06-01       Impact factor: 4.003

Review 2.  Pragmatic Treatment of Stiff Person Spectrum Disorders.

Authors:  Bettina Balint; Hans-Michael Meinck
Journal:  Mov Disord Clin Pract       Date:  2018-07-19

Review 3.  Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review.

Authors:  Hiroshi Nagafuji; Hidenori Yokoi; Masachika Fujiwara; Dai Sato; Koichiro Saito
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

4.  Anti-SOX1 antibody-positive paraneoplastic neurological syndrome presenting with Lambert-Eaton myasthenic syndrome and small cell lung cancer: A case report.

Authors:  Chunyang Li; Xiaolei Wang; Lihua Sun; Hui Deng; Yanqiu Han; Wenqi Zheng
Journal:  Thorac Cancer       Date:  2019-12-27       Impact factor: 3.500

5.  Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases.

Authors:  Le-Duy Do; Christian P Moritz; Sergio Muñiz-Castrillo; Anne-Laurie Pinto; Yannick Tholance; Sabine Brugiere; Yohann Couté; Oda Stoevesandt; Michael J Taussig; Véronique Rogemond; Alberto Vogrig; Bastien Joubert; Karine Ferraud; Jean-Philippe Camdessanché; Jean-Christophe Antoine; Jérôme Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.